Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cadila Gets FDA Nod for Arthritis Drug (India)

This article was originally published in PharmAsia News

Executive Summary

Major Indian pharmaceutical manufacturer Zydus Cadila Healthcare announced on Sept. 25 that it has received approval from the U.S. FDA for a new drug to treat rheumatoid arthritis. The FDA approval is for a 200mg dose of hydrochloroquine sulfate. The drug is one of a class of arthritis-fighting treatments known as disease modifying anti-rheumatic drugs (DMARD). DMARDs are designed to reduce the pain, inflammation, and joint damage caused by the disease for a period of several weeks or several months depending on the treatment. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts